BioCentury | Sep 15, 2016
Targets & Mechanisms

Bon voyage!

...Takeda is one of only two companies with a norovirus vaccine in clinical development. Its TAK-214...
...St Louis, Mo. Targets and Compounds CD300LF - CD300 molecule like family member TAK-214 ( Norovirus VLP intramuscular vaccine...
BioCentury | Jun 27, 2016
Clinical News

Norovirus VLP intramuscular vaccine: Phase IIb started

...began a double-blind, placebo-controlled, U.S. Phase IIb trial to evaluate a single dose of intramuscular TAK-214...
...3,400 healthy volunteers ages 18-49. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Norovirus VLP intramuscular vaccine ( TAK-214...
BioCentury | May 30, 2016
Strategy

Taking Takeda global

...global markets. TAK-003 is expected to start Phase III testing this year for dengue fever. TAK-214...
BioCentury | Oct 21, 2013
Clinical News

Norovirus VLP intramuscular vaccine: Phase I/II data

...A double-blind Phase I/II trial in 98 healthy volunteers aged 18-50 years showed that Norovirus VLP intramuscular vaccine missed...
...headache reported as the most common systemic reaction. Subjects received 2 vaccinations with placebo or Norovirus VLP intramuscular vaccine...
...details. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Norovirus VLP intramuscular vaccine...
BioCentury | Sep 27, 2010
Clinical News

Norovirus VLP intramuscular vaccine: Phase I started

...U.S. Phase I trial to evaluate 2 doses of 5, 15, 50 and 150 µg Norovirus VLP intramuscular vaccine...
...from GlaxoSmithKline. LigoCyte Pharmaceuticals Inc. , Bozeman, Mont. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Norovirus VLP intramuscular vaccine...
Items per page:
1 - 5 of 5